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Small cell lung cancer associated with
multiple paraneoplastic syndromes
Diana L. Franco1, Leslie Thomas2
 1    Department of Internal Medicine, Mayo Clinic AZ, Scottsdale, United States of America 
 2    Division of Nephrology, Mayo Clinic AZ, Scottsdale, United States of America
We report the case of a patient presenting with multiple severe electrolyte disturbances who was 
subsequently found to have small cell lung cancer. Upon further evaluation, she demonstrated three 
distinct paraneoplastic processes, including the syndrome of inappropriate antidiuretic hormone, 
Fanconi syndrome, and an inappropriate elevation in fibroblast growth factor-23 (FGF23). The patient 
underwent one round of chemotherapy, but she was found to have progressive disease. After 36 days 
of hospitalization, the patient made the decision to enter hospice care and later she expired.
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Cáncer de pulmón de células pequeñas asociado a múltiples síndromes paraneoplásicos
Se reporta el caso de una paciente que ingresó al hospital para evaluación de múltiples trastornos 
electrolíticos y, posteriormente, se le hizo el diagnóstico de cáncer de pulmón de células pequeñas. 
Tras la evaluación médica, se detectaron tres síndromes paraneoplásicos: síndrome de secreción 
inadecuada de hormona antidiurética, síndrome de Fanconi y elevación inapropiada del factor 23 
de crecimiento de fibroblastos. Se le administró quimioterapia sin éxito, por lo cual se decidió darle 
tratamiento paliativo y, un tiempo después, falleció.
Palabras clave: neoplasias pulmonares; síndromes paraneoplásicos; electrolitos; síndrome de Fanconi. 
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Small cell cancer may be associated with a 
number of paraneoplastic syndromes, including 
the syndrome of inappropriate antidiuretic hor-
mone (SIADH) (1).To our knowledge, only two 
cases of small cell cancer associated with 
Fanconi syndrome have been previously reported 
(2,3). Small cell cancer associated with isolated 
phosphate wasting without Fanconi syndrome 
has also been rarely reported, leading some 
to consider whether fibroblast growth factor 23 
(FGF23) played a role in those cases. Despite 
this speculation, FGF23 level was not measured 
in these patients.
We present a case of small cell cancer of the lung 
associated with three discreet paraneoplastic 
syndromes, including syndrome of inappropriate 
antidiuresis (SIAD), Fanconi syndrome, and tumor-
induced osteomalacia arising from an inappropriate 
increase in FGF23. This is the third reported case 
of SCC associated with generalized renal proximal 
tubule dysfunction (Fanconi syndrome) and the 
first report of small cell cancer associated with an 
inappropriately elevated FGF23 hormone level.
Case presentation
A 57-year-old woman with a 35-year smoking 
history presented with a cough productive of 
clear sputum, nausea, and decreased oral intake 
ongoing for one month. Her past medical history 
included hypertension, hyperlipidemia, chronic 
obstructive pulmonary disease, obesity, obstructive 
sleep apnea, and chronic hepatitis B infection. Her 
family history included leukemia (father), cancer of 
unknown primary (mother), thyroid cancer (sister), 
and bladder cancer (brother).
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Investigations
As shown in figure 1, computed tomography of the 
chest revealed a 3 x 1 cm mass in the posterior 
bronchus of the right upper lung and right-
sided paratracheal and supraclavicular adeno-
pathies. Lymph node biopsy demonstrated a 
nonhematopoietic malignant neoplasm with strong 
expression of CD56, consistent with small cell 
neuroendocrine carcinoma. 
Initial laboratory studies revealed multiple electrolyte 
abnormalities at presentation, including hyponatre-
mia, hypobicarbonatemia, and hypophosphatemia.
Although initially attributed to her anorexia and 
hypovolemic state, the patient’s hypoosmolar hypo-
natremia (Osm 266 mosmol/kg, Na 123 (135-145 
mmol/L) was found to persist despite restoration 
of euvolemia after several days in the hospital. 
In the setting of euvolemia and normotension, 
normal renal clearance (eGFR>60 ml/minute/1.73 
m2), normal thyroid and adrenal studies, adequate 
solute intake, and absence of renal sodium wasting 
(fractional excretion of sodium 0.005), the hypona-
tremic state continued (Na 122 mEq/L) along with 
increased urine osmolality (Uosm 545 mOsm/kg). 
This confirmed the presence of SIAD, likely related 
to the patient’s SCC.
A non-anion gap metabolic acidosis (arterial pH: 
7.374, pCO2: 30.5, serum HCO3-: 16 (22-29 
mmol/L)) was also identified. A high urine anion gap 
(46) was measured, consistent with a renal tubular 
acidosis. Glucosuria (1.0 mg/dl) in the setting of 
normal serum glucose (86 [70-100 mg/dl]), gener-
alized aminoaciduria, and hyperphosphaturia in the 
setting of hypophosphatemia were also observed. 
These findings were consistent with generalized 
dysfunction of the renal proximal tubule (i.e., 
Fanconi syndrome).
In the setting of severe hypophosphatemia and 
normal estimated glomerular filtration rate (eGFR), 
FGF23 would be expected to be low. However, an 
elevation of FGF23 was discovered: 500 RU/ml 
(reference value: <180 RU/ml). Other phosphaturic 
hormones were normal, including parathyroid 
hormone (47 pg/ml; reference: 15-65 pg/ml) and 
parathyroid hormone-related peptide (<0.2 pmol/L). 
As expected with an increased level of FGF23, 
1,25-dihydroxyvitamin D (1,25(OH)2D) was low (8 
pg/ml; reference: 18-78 pg/ml), despite a normal 
concentration (28 ng/ml; reference: 25-80 ng/ml) 
of 25-hydroxyvitamin D (25(OH)D) and normal 
eGFR (>60 ml/minute/1.73 m2). In this setting, 
the elevation of FGF23 was inappropriate and 
consistent with the presence of an independent 
paraneoplastic process related to SCC.
Treatment
As shown in figure 2, the patient received multiple 
doses of both oral and intravenous phosphate 
with minimal overall effect on serum phosphate 
concentration. The patient’s SCC was treated with 
carboplatin and etoposide.
Outcome and follow-up
Unfortunately, the patient’s multiple electrolyte 
abnormalities did not improve after initial tumor-
directed therapy. Follow-up imaging revealed a 
Figure 2. Graph showing the serum and urine phosphate levels 
with IV and oral phosphate replacements
Figure 1. Computed tomography of the chest showing the mass 
in the right upper lung
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rapid progression of tumor burden. Subsequently, 
the patient made the decision to enter hospice 
care, and she expired.
Discussion
This is the third report of small cell cancer associated 
with Fanconi syndrome (1,2). One of the two previ-
ously reported cases also involved concurrent SIAD.
FGF23 is a hormone produced in osteocytes and 
osteoblasts that regulates phosphate and vitamin 
D metabolism. It acts in the proximal tubule by 
down regulating the expression of luminal sodium-
dependent phosphate transporters leading to phos-
phaturia, and by down-regulating 1a-hydroxylase 
reducing vitamin D synthesis. It is synthesized as 
a pro-protein that is cleaved and glycosylated to 
produce FGF23 fragments (4).
FGF23 is measured by immunometric enzyme-
linked immunosorbent assay (ELISA). Commercially 
there are two formats available: The “intact” 
assay (iFGF23), that recognizes distant epitopes 
at the cleavage site, and the ‘C-terminal’ assay 
(cFGF23), which recognizes two distinct epitopes, 
in the terminal portion of molecule allowing the 
measurement of the FGF23 fragments (4,5).
Circulating FGF23 levels are governed chiefly 
by changes in serum phosphate and by the 
vitamin D endocrine system. In states of relative 
hyperphosphatemia or increased production of 
1,25(OH)2D, FGF23 concentration rises, pro-
moting renal phosphate wasting and inhibition 
of 1a-hydroxylase with subsequent attenuation 
of serum phosphate and 1,25(OH)2D levels. In 
the condition of tumor-induced osteomalacia, 
unregulated phosphatonin (e.g., FGF23) production 
leads to hyperphosphaturia, low circulating levels 
of 1,25(OH)2D, severe hypophosphatemia, and, 
eventually, osteomalacia. In this case, neither 
osteomalacia nor symptoms of osteomalacia were 
noted. Most documented cases of tumor-induced 
osteomalacia have involved benign mesenchymal 
tumors, specifically solitary, non-aggressive ap-
pearing soft tissue or osseous lesions (6). However, 
there are cases in which infiltrating aggressive 
tumors are seen (7).In a recent review of patients 
with small cell cancer with apparent tumor-
related disturbances of phosphate metabolism, six 
patients demonstrated isolated renal phosphate 
wasting without Fanconi syndrome and two 
demonstrated oncogenic osteomalacia (3). Of 
those cases, three had concurrent SIADH, one 
had concurrent Cushing’s syndrome, and one had 
both concurrent SIADH and Cushing’s syndrome. 
In none of those cases was FGF23 measured. 
In this patient, hypophosphatemia was promoted 
by two independent processes: Generalized proxi-
mal tubular dysfunction and an inappropriately 
elevated FGF23.
Conclusions
Small cell cancer may be associated with a variety 
of paraneoplastic syndromes, including rarely 
encountered processes such as Fanconi syndrome 
and tumor-induced osteomalacia. Restoration of 
serum phosphate to normal levels in individuals 
with small cell cancer-associated Fanconi syndrome 
or tumor-induced osteomalacia may prove difficult 
despite aggressive oral and intravenous phosphate 
replacement. FGF23 should be measured in any 
patient with difficulties to manage hypophospha-
temia and hyperphosphaturia.
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